[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100448244":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":21,"locations":30,"responsibleParty":49,"collaborators":21,"id":52,"slug":21,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":21,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":21,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":21,"overallStatus":33,"whyStopped":21,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Postpartum dural puncture headache following dural puncture from Tuohy needle","EXPERIMENTAL","Subjects identified as experienced a post dural puncture headache after a confirmed dural puncture from a Tuohy needle will receive an IV administration of the study medications neostigmine and glycopyrrolate.",[13,14],"Drug: Neostigmine","Drug: Glycopyrrolate",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Neostigmine","IV infusion 20 μg\u002Fkg over 10 minutes repeated every 8 hours for a maximum of 3 doses",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Glycopyrrolate","IV infusion 4 μg\u002Fkg over 10 minutes repeated every 8 hours for a maximum of 3 doses",[9],[27],{"name":28,"affiliation":5,"role":29},"Mark Rollins, MD, PhD","PRINCIPAL_INVESTIGATOR",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States",{"type":39,"coordinates":40},"Point",[41,42],-92.4699,44.02163,{"lat":42,"lon":41},[45],{"name":28,"role":46,"phone":47,"phoneExt":21,"email":48},"CONTACT","(507) 422-0662","rollins.mark@mayo.edu",{"type":29,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Mark D. Rollins","Principal Investigator","100448244",false,"NCT05116930","Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture","Neostigmine and Glycopyrrolate for the Treatment of Post Dural Puncture Headache After Known Dural Puncture With a Tuohy Needle: A Pilot Study","Inclusion Criteria:\n\n* Post-dural puncture headache (PDPH) after documented dural puncture with Tuohy needle during placement of epidural analgesia for labor and no other explanation for headache (HA).\n* Onset of HA within 72 hours of delivery.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Visual analog scale (NRS) score \\\u003C 4.\n* History of migraine headaches.\n* Asthma.\n* Arrhythmia.\n* Heart block.\n* Myasthenia gravis.\n* Inability to understand pain scores and other questionnaires.\n* Inability to speak English.\n* Contraindication to acetaminophen or NSAIDs.\n* Temperature \\> 38.5 C.\n* Prior EBP done for this HA.","FEMALE","18 Years","54 Years",{"count":62,"type":63},18,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.",[69],"Post-Dural Puncture Headache","2026-03-18",{"date":72,"type":73},"2026-03-23","ACTUAL",{"date":75,"type":73},"2021-11-19",{"date":77,"type":63},"2027-12",{"name":5,"class":6},1]